| Recruiting | Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carci NCT06969833 | Centre Oscar Lambret | N/A |
| Recruiting | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors NCT07001592 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 1 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test NCT06445621 | Uppsala University Hospital | — |
| Recruiting | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07022535 | The University of Hong Kong | Phase 2 |
| Completed | The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilo NCT06144853 | Odense University Hospital | — |
| Recruiting | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Nudge to Gynecologic Oncology NCT06451263 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib NCT05887609 | University of Colorado, Denver | Phase 2 |
| Unknown | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer NCT05960630 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Completed | Choices About Genetic Testing And Learning Your Risk With Smart Technology NCT06184867 | Rutgers, The State University of New Jersey | N/A |
| Recruiting | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or Hig NCT05080556 | University College, London | Phase 2 |
| Unknown | Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer NCT05792254 | Ruijin Hospital | N/A |
| Terminated | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05708924 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Ep NCT06087289 | Novakand Pharma AB | Phase 1 / Phase 2 |
| Recruiting | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer NCT05071937 | Alexander B Olawaiye, MD | Phase 2 |
| Active Not Recruiting | Genetic Testing in African Americans NCT05591131 | Augusta University | N/A |
| Recruiting | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial NCT05445778 | AbbVie | Phase 3 |
| Terminated | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Tr NCT05581719 | Enlivex Therapeutics RDO Ltd. | Phase 1 / Phase 2 |
| Recruiting | Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy NCT05597683 | Gangnam Severance Hospital | N/A |
| Recruiting | Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer NCT04701645 | Brigham and Women's Hospital | Phase 1 |
| Recruiting | Development and Management of Registry in Patients With Gynecologic Cancer in Korea NCT05912972 | Asan Medical Center | — |
| Recruiting | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovaria NCT05009082 | AGO Study Group | Phase 3 |
| Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors NCT04196257 | Bio-Path Holdings, Inc. | Phase 1 |
| Unknown | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian C NCT05622890 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive R NCT05335993 | CanariaBio Inc. | Phase 2 |
| Active Not Recruiting | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemothera NCT05406674 | The Netherlands Cancer Institute | Phase 2 |
| Unknown | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases NCT05353582 | Sun Yat-sen University | Phase 2 |
| Unknown | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei NCT03976973 | Mucpharm Pty Ltd | Phase 2 |
| Recruiting | Using Aspirin to Improve Immunological Features of Ovarian Tumors NCT05080946 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers NCT05041257 | AbbVie | Phase 2 |
| Recruiting | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes NCT04907643 | Cedars-Sinai Medical Center | N/A |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC NCT04983550 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Unknown | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT04846842 | Lee's Pharmaceutical Limited | Phase 2 |
| Terminated | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian C NCT04611126 | Inge Marie Svane | Phase 1 / Phase 2 |
| Recruiting | Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI) NCT05718726 | Hampshire Hospitals NHS Foundation Trust | — |
| Completed | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib NCT04676334 | pharmaand GmbH | Phase 3 |
| Recruiting | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | Tempus Priority Study: A Pan-tumor Observational Study NCT05179824 | Tempus AI | — |
| Active Not Recruiting | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117 | CanariaBio Inc. | Phase 3 |
| Completed | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Pe NCT04296890 | ImmunoGen, Inc. | Phase 3 |
| Unknown | Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival NCT04402333 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Unknown | Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR NCT04295577 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Adv NCT04209855 | AbbVie | Phase 3 |
| Completed | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors NCT03023319 | Nagla Abdel Karim | Phase 1 |
| Completed | Genomic BRCA and Extensive ovArian Cancer Testing NCT04027868 | ARCAGY/ GINECO GROUP | — |
| Completed | Phase I Trial HIPEC With Nal-irinotecan NCT04088786 | Stony Brook University | Phase 1 |
| Unknown | Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC NCT04122885 | University Hospital Tuebingen | — |
| Completed | Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients NCT04537702 | Duke University | N/A |
| Active Not Recruiting | A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors NCT04022213 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Detecting Activity to Support Healing NCT03211806 | University of Pittsburgh | N/A |
| Unknown | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritonea NCT03430700 | University College, London | Phase 2 |
| Completed | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (in NCT03657043 | Seagen Inc. | Phase 2 |
| Unknown | Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Periton NCT03693248 | Seoul National University Hospital | Phase 3 |
| Completed | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advance NCT06599749 | University Hospital, Basel, Switzerland | — |
| Completed | Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epi NCT03359811 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer NCT03126812 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | Real-life Use of Niraparib in a Patient Access Program in Norway NCT04785716 | Kristina Lindemann | — |
| Active Not Recruiting | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases NCT02758951 | Koen Rovers | Phase 2 / Phase 3 |
| Completed | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT02855944 | pharmaand GmbH | Phase 3 |
| Completed | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer NCT02915523 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib NCT02873962 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer NCT02973750 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Completed | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer NCT02865811 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcin NCT02487849 | Krankenhaus Barmherzige Schwestern Linz | Phase 2 |
| Completed | A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers NCT02824328 | Duke University | — |
| Completed | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers NCT02728830 | AA Secord | EARLY_Phase 1 |
| Completed | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer NCT02657889 | Tesaro, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Long-Term Responders on Olaparib NCT02489058 | University Health Network, Toronto | — |
| Unknown | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer NCT02534922 | Oncolix, Inc. | Phase 1 |
| Completed | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer NCT02668913 | Geoff Hall | N/A |
| Unknown | Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy NCT02741167 | University of Zurich | — |
| Unknown | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies NCT02433626 | Critical Outcome Technologies Inc. | Phase 1 |
| Completed | Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients NCT02470299 | New Mexico Cancer Research Alliance | N/A |
| Completed | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid NCT01968213 | pharmaand GmbH | Phase 3 |
| Completed | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer NCT01556841 | University College, London | Phase 2 |
| Completed | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian T NCT01891344 | pharmaand GmbH | Phase 2 |
| Completed | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Canc NCT03332576 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer NCT01669798 | AA Secord | Phase 2 |
| Completed | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemot NCT01767675 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Accelerating Gastrointestinal Recovery NCT01704651 | Jamie N. Bakkum-Gamez | Phase 3 |
| Completed | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cance NCT01610206 | Linda R Duska | Phase 2 |
| Withdrawn | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer NCT01661868 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT01649336 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer NCT01591772 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer NCT01580696 | COL George Peoples, MD, FACS | Phase 1 / Phase 2 |
| Terminated | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovari NCT01493505 | Amgen | Phase 3 |
| Completed | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cance NCT01416038 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer NCT01471483 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phas NCT01482715 | pharmaand GmbH | Phase 1 / Phase 2 |
| Completed | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers NCT01447706 | Merrimack Pharmaceuticals | Phase 2 |
| Completed | Pelvic Floor Disorders in Survivors of Gynecologic Malignancies NCT01370122 | Abramson Cancer Center at Penn Medicine | — |
| Completed | Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive NCT01262040 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With NCT01248962 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian T NCT01248273 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab NCT01223235 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer NCT01188876 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Stud NCT01091428 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum NCT01099644 | Y-mAbs Therapeutics | Phase 1 |
| Completed | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer NCT01104675 | CASI Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer NCT01083537 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies NCT01065662 | Susana M. Campos, MD | Phase 1 |
| Terminated | Abraxane/Bevacizumab NCT01821859 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT NCT01276574 | Turku University Hospital | — |
| Completed | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Ca NCT01048814 | Precision Therapeutics | — |
| Terminated | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer NCT00910000 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health NCT00870233 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies NCT00856180 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer NCT00850772 | Queensland Centre for Gynaecological Cancer | Phase 3 |
| Completed | Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube NCT00692900 | University of Pittsburgh | Phase 1 |
| Suspended | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal NCT00753480 | Genentech, Inc. | Phase 1 |
| Completed | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma NCT00768144 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fal NCT00801320 | Beth Israel Deaconess Medical Center | N/A |
| Withdrawn | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00634894 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. NCT00637390 | University of Michigan Rogel Cancer Center | Phase 1 |
| Unknown | Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Or NCT00652119 | Massachusetts General Hospital | Phase 1 |
| Completed | A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Canc NCT00683241 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer NCT00672295 | AA Secord | Phase 1 |
| Completed | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis NCT00491855 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | ChemoFx® PRO - A Post-Market Data Collection Study NCT00669422 | Precision Therapeutics | — |
| Terminated | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT00408070 | UConn Health | Phase 2 |
| Unknown | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy NCT02349958 | Bay Area Gynecology Oncology | Phase 2 |
| Completed | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers NCT00343044 | Benaroya Research Institute | Phase 2 |
| Completed | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer NCT00281632 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT00267696 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer NCT00230542 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients NCT00268918 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer NCT00499512 | M.D. Anderson Cancer Center | — |
| Completed | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube NCT00096993 | Genentech, Inc. | Phase 2 |
| Completed | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Prima NCT00461786 | Eli Lilly and Company | Phase 2 |
| Terminated | Letrozole in Patients With Ovarian Tumors NCT00505661 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer NCT00501644 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Depression Treatment and Screening in Ovarian Cancer Patients NCT00515372 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer NCT00061308 | GlaxoSmithKline | Phase 2 |
| Completed | Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum an NCT02728622 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Phase 3 |
| Terminated | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive an NCT00055432 | Eli Lilly and Company | Phase 2 |
| Completed | A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopia NCT00189358 | AGO Study Group | Phase 2 |